IPO Details
Bidding Dates
11 Dec '24 - 13 Dec '24
Minimum Investment
₹14,823 / 1 Lot (27 Shares)
Price Range
₹522 - ₹549
Maximum Investment
₹1,92,699 / 13 Lot (351 Shares)
Retail Discount
-
Issue Size
₹3,042.62 crore
Investor category and sub category
Qualified Institutional Buyers | Retail Individual Investors | Non-institutional Investors |Sai Life Sciences IPO Dates
Important dates with respect to IPO allotment and listing
Sai Life Sciences IPO Opening Date
Dec 11, 2024
Sai Life Sciences IPO Closing Date
Dec 13, 2024
Sai Life Sciences IPO Allotment Date
Dec 16, 2024
Sai Life Sciences IPO Initiation of Refunds
Dec 17, 2024
Sai Life Sciences IPO Listing Date
Dec 18, 2024
Sai Life Sciences IPO Subscription Details
| Date | QIB | NII | Retail | Total |
|---|---|---|---|---|
Day 1Dec 11, 2024 |
0.00 | 0.01 | 0.03 | 0.02 |
About Sai Life Sciences IPO
Sai Life Sciences IPO is a book-built issue aiming to raise ₹3,042.62 crore. It includes a fresh issue of 1.73 crore shares worth ₹950.00 crore and an offer for sale of 3.81 crore shares amounting to ₹2,092.62 crore.
The IPO opens for subscription on December 11, 2024, and closes on December 13, 2024. Allotment is expected on December 16, 2024, with the listing anticipated on December 18, 2024, on both the BSE and NSE.
The IPO price band is set at ₹522 to ₹549 per share, with a minimum lot size of 27 shares. Retail investors need a minimum investment of ₹14,823. For non-institutional investors, small NII can invest in 14 lots (378 shares) worth ₹2,07,522, while large NII require 68 lots (1,836 shares) amounting to ₹1,007,964.
Kotak Mahindra Capital, Jefferies India, Morgan Stanley India, and IIFL Securities are the book-running lead managers. Kfin Technologies Limited is the registrar for the issue. Investors can refer to the Sai Life Sciences IPO RHP for detailed information about the offering.
Industry Outlook
- The global pharmaceutical market, valued at USD 1,451 billion in 2023, is expected to grow at a CAGR of 6.2% to reach USD 1,956 billion by 2028. This growth is driven by factors like an aging population, rising chronic diseases, and increased health consciousness.
- India's Contract Research, Development, and Manufacturing Organisation (CRDMO) industry is projected to grow by 14% annually, from USD 7.3 billion in 2023 to USD 14.1 billion by 2028.
- The pre-clinical development segment in India's CRDMO industry is expected to grow at a CAGR of 15.7% from FY23 to FY28. This growth is driven by enhanced R&D capabilities in India.
Sai Life Sciences IPO Objectives
The company plans to allocate the net proceeds from the issuance to the following purposes:
- The funds will be used to repay or prepay outstanding borrowings, either in full or part, reducing the company’s debt burden.
- The remaining funds will be allocated towards general corporate purposes.
About Sai Life Sciences Limited
Sai Life Sciences Limited is a leading Contract Research, Development, and Manufacturing Organisation (CRDMO) that provides comprehensive services across the drug discovery, development, and manufacturing value chain. The company serves global pharmaceutical and biotechnology firms, offering both contract research (CRO) and contract development and manufacturing (CDMO) capabilities.
With a strong presence in key global markets, Sai Life Sciences has become one of the fastest-growing Indian CRDMOs, driven by a 117% growth in its commercial and late-stage product portfolio since 2019. The company operates research laboratories in major innovation hubs like Boston (US) and Manchester (UK), complemented by large-scale facilities in India, enabling cost-effective solutions for drug discovery and manufacturing.
As of September 30, 2024, Sai Life Sciences had served over 280 pharmaceutical companies, including 18 of the top 25 global pharma companies. Its portfolio includes over 170 innovator pharmaceutical products, with several drugs approved and commercially available.
Sai Life Sciences is committed to sustainability, incorporating energy-saving measures, increasing the use of renewable energy, and reducing carbon emissions. The company is also a member of the Pharmaceutical Supply Chain Initiative (PSCI) and has received a silver rating for sustainability by EcoVadis.
Peer Details
According to RHP, the following are the listed peers of Sai Life Sciences Limited:
- Divi's Laboratories Limited
- Suven Pharmaceuticals Limited
- Syngene International Limited
How To Check the Allotment Status of the Sai Life Sciences IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
How to apply for Sai Life Sciences IPO online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Sai Life Sciences IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
Contact Details of Sai Life Sciences IPO
Registered office: Plot No. DS-7,IKP Knowledge Park, Turkapally Village, ShameerpetMandal, Medchal–Malkajgiri District, Hyderabad 500078, Telangana, India
Phone: +9140 6815 6000
E-mail: investors@sailife.com
Sai Life Sciences IPO Reservation
|
Investor Category |
Shares Offered |
|
QIB Shares Offered |
Not more than 50.00% of the Net offer |
|
Retail Shares Offered |
Not less than 35.00% of the Net Issue |
|
NII (HNI) Shares Offered |
Not less than 15.00% of the Net Issue |
Sai Life Sciences IPO Lot Size
|
Application |
Lots |
Shares |
Amount |
|
Retail (Min) |
1 |
27 |
₹14,823 |
|
Retail (Max) |
13 |
351 |
₹1,92,699 |
|
HNI (Min) |
14 |
378 |
₹2,07,522 |
|
S-HNI (Max) |
67 |
1,809 |
₹9,93,141 |
|
B-HNI (Min) |
68 |
1,836 |
₹10,07,964 |
Sai Life Sciences IPO Anchor Investors Details
Sai Life Sciences IPO successfully secured ₹912.79 crore from anchor investors. The anchor bidding for the IPO was conducted on December 10, 2024.
|
Bid Date |
December 10, 2024 |
|
Shares Offered |
16,626,336 |
|
Anchor Portion Size (in ₹ crore) |
912.79 |
|
Anchor lock-in period end date for 50% shares (30 Days) |
January 15, 2025 |
|
Anchor lock-in period end date for remaining shares (90 Days) |
March 16, 2025 |
Sai Life Sciences IPO Promoter Holding
The company's promoters include Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners, and Tulip Partners.
|
Share Holding Pre-Issue |
40.48% |
|
Share Holding Post Issue |
_ |
Key Performance Indicators for Sai Life Sciences IPO
The Sai Life Sciences IPO has a market capitalisation of ₹11,418.63 crore as of March 31, 2024.
|
KPI |
Value |
|
ROE |
11.79% |
|
ROCE |
15.96% |
|
RoNW |
8.13% |
|
P/BV |
10.18 |
|
PAT Margin (%) |
5.65 |
Sai Life Sciences IPO Prospectus
Sai Life Sciences IPO Registrar and Lead Managers
Sai Life Sciences IPO Lead Managers
- Kotak Mahindra Capital Company Limited
- Jefferies India Private Limited
- Morgan Stanley India Company Pvt Ltd
- Iifl Securities Ltd
Registrar for Sai Life Sciences IPO
Kfin Technologies Limited
- Contact Number: 04067162222, 04079611000
- Email Address: sailifesciences.ipo@kfintech.com
Website: Sai Life SciencesIPO Registrar
Sai Life Sciences IPO Financials
| Particulars | Year ending on March 31, 2024 | Year ending on March 31, 2023 | Year ending on March 31, 2022 |
|---|---|---|---|
| Revenue from Operation (in ₹ million) | 14,651.78 | 12,171.39 | 8,695.93 |
| Profit After Tax (PAT) (in ₹ million) | 828.09 | 99.89 | 62.26 |
| Total Borrowings (in ₹ million) | 7,101.63 | 6,992.29 | 7,513.18 |
| Net Worth (in ₹ million) | 9743.37 | 8872.86 | 8777.58 |
| Return on Capital Employed(%) | 10.26 | 5.13 | 3.21 |
| Return on Equity (%) | 8.49 | 1.12 | 0.71 |
| Debt/ Equity (x) | 0.75 | 0.80 | 0.84 |
| Earning Per Share (EPS)-in absolute ₹ | 4.53 | 0.55 | 0.34 |
Know before investing
Strengths
9-
Sai Life Sciences Limited boasts a diverse portfolio of commercial and under-development molecules, including drugs and APIs in various clinical trial phases.
-
The fastest-growing Indian CRDMO among listed peers, showing strong revenue and profitability growth from 2022 to 2024.
-
The company has fast-growing integrated discovery capabilities, focusing on biology, chemistry, and DMPK services, which are attracting an increasing number of customers.
-
Sai Life Sciences Limited has long-standing relationships with a diverse base of existing and new customers, including 18 out of the top 25 pharmaceutical companies.
-
The company's modern R&D infrastructure and strong regulatory track record support its capabilities in providing end-to-end solutions and maintaining high-quality standards.
-
Fastest-growing CRDMO with improving profitability and revenue growth metrics.
-
The contract research revenue surged from ₹2,737.28M in FY 2022 to ₹4,971.70M in FY 2024, with a growing base of over 60 customers in integrated drug discovery programs.
-
Ongoing investments in Unit IV and VI facilities at Bidar and Hyderabad labs expansion aim to accommodate the rising demand from Discovery services and commercial product growth.
-
Technology-enabled processes and workforce training are enhancing operational efficiency, improving profitability, and ensuring high-quality service delivery across all functions.
Risks
9-
The company's financial performance is heavily reliant on securing business from biotechnology and pharmaceutical customers, making it vulnerable to industry trends and uncertainties beyond its control.
-
The company's success depends on its research and development activities, which are costly, time-consuming, and have a low success rate. If outcomes are not achieved, future growth might be at risk.
-
Sai Life Sciences Limited is subject to extensive government regulation; failure to obtain, maintain, or renew necessary permits and approvals could adversely impact its operations and financial health.
-
Failing to meet customer standards during audits and inspections could harm the company's reputation, leading to the termination of ongoing projects and potential financial losses.
-
Delays or interruptions in manufacturing could hinder the company's ability to meet customer demand.
-
Losing key customers or large contracts could materially and adversely impact Sai Life Sciences Limited's business, financial condition, and operational results.
-
Dependence on a key customer who contributed 8% of revenue for six months ending September 2024 could severely impact business performance.
-
Animal testing involving rats and mice, with plans for future expansion to primates, risks adverse publicity, legal liability, and potential protests.
-
Sai Life Sciences Inc., a subsidiary, reported consistent losses of ₹45.66M (2024), ₹150.60M (2023), ₹125.97M (2022), and ₹93.10M (six months of 2024).
Login to Angel One App / Website & click on IPO
Select desired IPO & tap on "Apply"
Enter UPI ID, set quantity/price & submit
Accept mandate on the UPI app to complete the process
Login to Angel One App / Website
Choose IPO section on Home Page
Click IPO Orders
Chose the IPO application you want to view the status for
Sai Life Sciences IPO FAQs
Sai Life Sciences IPO is a book-built issue IPO. It will be open from December 11, 2024, to December 13, 2024.
The Basis of Allotment will happen on Monday, December 16, 2024.
The IPO subscription window will open on December 11, 2024.
The minimum lot size retail investors can subscribe to is 1 lot, and the lot size is 27 shares.
The listing date for Sai Life Sciences Limited is Wednesday, December 18, 2024.
The issue size of the Sai Life Sciences IPO is up to ₹3,042.62 crore, with a fresh issue of ₹950.00 crore and an offer for sale of ₹2,092.62 crore.
The open and close dates for Sai Life Sciences IPO are from December 11, 2024 to December 13, 2024.
Listing gains cannot be ascertained before the listing of the IPO on the stock exchange.
- Multiple Submissions: Use different Demat accounts to make multiple applications.
- Higher Price Band Bidding: Opt for bidding at the cut-off price or higher price band.
3. Timely Subscription: Ensure you subscribe to the IPO within the specified time frame.
You must complete the payment process by logging in to your UPI handle and approving the payment mandate.
You can submit only one application using your PAN card.
To read Sai Life Sciences’s financial statements, download the IPO’s RHP document.
Pre-apply allows investors to apply for the Sai Life Sciences IPO two days before the subscription period opens, ensuring an early submission of your application.
Your order will be placed when the IPO opens for bidding, and a UPI request will follow within 24 hours.
You will receive a notification once your order is successfully placed with the exchange after the bidding starts.
Kfin Technologies Limited is the registrar responsible for managing the IPO allotment process and handling investor queries.
Sai Life Sciences IPO is a mainboard IPO that will be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
